試す 金 - 無料
Domestic pharma player
Capital Market
|December 08, 2025
Targeting high-potential therapeutic areas to drive growth
-
Corona Remedies is an India-focused branded pharmaceutical formulation company developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
As of June 30, 2025, the diverse portfolio included 71 brands across therapeutic areas. Women’s healthcare brands span the entire lifecycle, from adolescence to infertility, pregnancy, post-pregnancy, and pre and post menopause. In cardio-diabeto, it provides treatments across all stages of diabetes, from insulin resistance and pre-diabetes to diabetes and related complications. In pain management, the portfolio includes four dosage forms, including tablets, capsules, sprays and injections. While in urology, brands address multiple disorders, including benign prostatic hyperplasia, overactive bladder, urinary tract infections and stone management.
There are two manufacturing facilities, located in Gujarat and Himachal Pradesh. Manufacturing facilities were spread over an aggregate of 2.83 hectares and had an aggregate installed capacity for formulations of 1,285.44 million units per annum, with a total of 11 production lines, end June 2025. It is in the process of commissioning a hormone manufacturing facility in Gujarat in Q1 FY 2027.
The pan-India marketing and distribution network comprises 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
このストーリーは、Capital Market の December 08, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Capital Market からのその他のストーリー
Capital Market
Forging Ahead
Fourth largest manufacturer of complex and safety-critical heavy forged and machined components in India
3 mins
January 05, 2026
Capital Market
Home-made flavor
Outperforming profitable companies over one and three years set to attract enhanced participation of local investors
5 mins
January 05, 2026
Capital Market
Cool winds
Softening inflation in India and the US and encouraging domestic economic data raise hopes of further interest rate cuts
39 mins
January 05, 2026
Capital Market
Specializes in niche products to banks
ASL'senterprise-technology platformcomprises annuity-driven software revenue with engineering execution capability, diversified geography and sustained innovation
3 mins
January 05, 2026
Capital Market
Fun to Be a Financial Planner
Don't know when, don't know where, just chant SIP and Asset Allocation
2 mins
January 05, 2026
Capital Market
Precious collection
Gold and silver witnessed a remarkable year amid excellent safe-haven buying
4 mins
January 05, 2026
Capital Market
ICE will not disappear soon
Reduced subsidies, gaps in infrastructure, and GST reforms have delayed EV adoption
3 mins
January 05, 2026
Capital Market
Margins to improve in H2FY26
Lower cost of deposits, the sharp 100 bps CRR cut, improving loan growth and stable Casa to aid margins improvement
8 mins
December 08, 2025
Capital Market
Cautiously optimistic
Domestic prices turn soft in Q2FY2026
3 mins
December 08, 2025
Capital Market
Eying pan-India presence
Leadership in North-East, presence in South and East and thrust on being carbon negative will drive growth
3 mins
December 08, 2025
Listen
Translate
Change font size
